Viewing Study NCT03787602


Ignite Creation Date: 2025-12-25 @ 3:38 AM
Ignite Modification Date: 2026-03-11 @ 3:41 AM
Study NCT ID: NCT03787602
Status: UNKNOWN
Last Update Posted: 2023-03-02
First Post: 2018-12-06
Is Gene Therapy: True
Has Adverse Events: False

Brief Title: Navtemadlin (KRT-232) With or Without Anti-PD-1/Anti-PD-L1 for the Treatment of Patients With Merkel Cell Carcinoma
Sponsor: Kartos Therapeutics, Inc.
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module